Biosimilars Should Face Patent Challenges Only After Approval - Novartis
This article was originally published in The Pink Sheet Daily
Executive Summary
But Novartis’ idea is not reflected in any biosimilars legislation introduced to date.
You may also be interested in...
Patent Challenge Mechanism For FOBs Should Be Scrapped, FTC Says
Report views early patent resolution as unnecessary and potentially harmful to patent incentives and consumers.
Patent Challenge Mechanism For FOBs Should Be Scrapped, FTC Says
Report views early patent resolution as unnecessary and potentially harmful to patent incentives and consumers.
Follow-On Biologics Study By FTC Aims “To Strike The Right Balance”
FTC appears skeptical of generic exclusivity for biologics, but the approval procedure would prove a critical factor.